| Title： | Chinese expert consensus on off-label administration of tocilizumab in rheumatic diseases |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | Clinicians at all levels (rheumatology, pharmacy, pediatric rheumatology and other related fields) |
| Evidence classification method： | The rating system of the Centre for Evidence-Based Medicine of the University of Oxford 2009 was adopted, in which the level of evidence was divided into level 1 (1a, 1b, 1c), level 2 (2a, 2b, 2c), level 3 (3a, 3b), level 4 and level 5, and the recommended level was divided into A, B, C, D and E |
| Development unit： | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University |
| Registration time: | 2024-01-30 |
| Registration number： | PREPARE-2023CN510 |
| Purpose of the guideline: | IL-6 targeted drugs in the world currently include Siltuximab targeting IL-6, Tocilizumab, Sarilumab and Satralizumab targeting IL-6 receptor, and Janus kinase (JAK) inhibitors. In China, siltuximab, tocilizumab and JAK inhibitors have been marketed. There are few reports on the application of siltuximab in patients with rheumatic diseases. The expert consensus on the off-label administration of JAK inhibitors in the treatment of rheumatic diseases has been published. The off-label administration of tocilizumab in clinical practice of rheumatic diseases is very common and increasing. Therefore, it is necessary to form an expert consensus aiming to provide the reference for rational use of tocilizumab among clinicians and the pharmacovigilance monitoring. |
Latest registration
